In this trial we examined the efficacy and safety of linifanib , an oral , potent , selective tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor families , with mFOLFOX6 , compared with bevacizumab and mFOLFOX6 , in previously treated metastatic CRC .